Study details
Enrolling now
Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas
Proton Collaborative Group
NCT IDNCT02598349ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
60
Study length
about 25 years
Ages
18+
Locations
4 sites in FL, IL, MI +1
What this study is about
This trial is testing if proton radiation combined with capecitabine improves outcomes in people who cannot have surgery for pancreatic cancer. The goal is to see if more patients can undergo curative surgery and improve local disease control.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Proton Radiation
- 2.Take Capecitabine
- 3.Undergo Surgical resection
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Oral
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
capecitabine
Drug routes
oral (Oral Tablet)
Endpoints
Primary: Overall survival at 12 months after radiation therapy
Procedures
radiation, surgery
Body systems
Oncology